Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield

This article compares Johnson & Johnson (JNJ) and AbbVie (ABBV) for dividend investors, highlighting J&J's safer, diversified portfolio and 64-year dividend streak against AbbVie's higher yield but greater concentration in immunology. While J&J offers a secure dividend with a AAA-rated balance sheet, AbbVie's recent acquisition and focus on post-Humira growth via drugs like Skyrizi present a higher-risk, potentially higher-reward scenario for total return. The author leans towards J&J for income and AbbVie for total return, based on their differing risk profiles and growth strategies.